Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in patients with ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Langer, Corey J., Novello, Silvia, Park, Keunchil, Krzakowski, Maciej, Karp, Daniel D., Mok, Tony, Benner, Rebecca J., Scranton, Judith R., Olszanski, Anthony J., Jassem, Jacek
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067944/
https://ncbi.nlm.nih.gov/pubmed/24888810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.4932
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados